Biofrontera Inc (BFRI)

Biofrontera Inc. reported its strongest second quarter and first half in company history for Q2 2026, driven by a 33% increase in net product revenue and 30% growth in Ameluz unit volume. The company achieved significant gross margin expansion to 80% following a strategic transaction in October 2025 and improved adjusted EBITDA. Biofrontera is navigating an ITC exclusion order on its RhodoLED XL lamp and is preparing for a Q1 2027 launch for superficial basal cell carcinoma.

Biofrontera Inc. (NASDAQ: BFRI) announced strong financial results for the second quarter and first half of 2026, driven by a 32.9% increase in net product revenue to $12.0 million for Q2 2026. The company achieved significant improvements in gross margin, reaching 80%, and substantially reduced its net loss and Adjusted EBITDA loss compared to the prior year, nearing cash flow breakeven. These positive results are attributed to a restructured cost base, disciplined commercial organization, and growing demand for Ameluz®, with ongoing developments for new indications.

Biofrontera reported strong Q2 2026 results with a 33% increase in net product revenue to $12 million and gross margin of 80%, achieving near breakeven adjusted EBITDA. The company highlighted ongoing commercial momentum, including an 18.6% increase in first-half order count, and provided updates on its clinical pipeline, expecting potential FDA approval for superficial basal cell carcinoma in Q1 2027. Despite a partial import ban on its RhodoLED XL lamp due to an ITC ruling, Biofrontera is implementing a remediation plan and remains confident in its full-year revenue goals, emphasizing its strategic growth model through existing infrastructure and expanded indications.

Biofrontera Inc (BFRI) reported strong Q2 2026 results, driven by significant Ameluz growth and successful commercial expansion, leading to increased revenue and improved gross margins. Despite heightened operating expenses and competition, the company maintains a solid cash position and projects 30-35% revenue growth for the full year 2026. Biofrontera is also advancing its pipeline and exploring strategic partnerships for international expansion.

Biofrontera Inc. reported increased net product revenue of $12.0 million for Q2 2026 and $22.1 million year-to-date, driven by Ameluz sales, with a narrowed net loss. However, the company flagged substantial doubt about its ability to continue as a going concern due to inadequate capital resources for the next 12 months, and it faces impacts from a May 2026 U.S. International Trade Commission order restricting the import and sale of certain products. Management plans to address liquidity through continued sales expansion, potential milestone payments, and securing additional financing.